title: Effect of hCG priming on embryonic development of immature oocytes collected from unstimulated women with polycystic ovarian syndrome.
abstract: BACKGROUND
  The effect of hCG priming on oocyte maturation and subsequently outcome in IVM cycles has remained a debated issue. A randomized controlled study was performed to investigate whether or not hCG priming prior to oocyte aspiration can improve the developmental competence of immature oocytes from unstimulated ovaries in women with polycystic ovarian syndrome (PCOS).
  
  
  METHODS
  Eighty two patients with PCOS underwent IVM cycles. Each patient was randomly assigned to the hCG-primed (10,000 IU) or non-primed groups 36-38 hours before oocyte retrieval depending on the computerized random table. After the oocytes had in vitro matured, fertilization, culture and embryo transfer were performed.
  
  
  RESULTS
  The average number of cumulus-oocyte complexes (COCs) recovered was 13.80 and 14.35 in the hCG-primed and non-primed groups, respectively (p>0.05). The maturation rate of COCs was significantly improved in the hCG-primed group (55.43% vs. 42.29%; p<0.05). The fertilization and cleavage rates were comparable between the groups. The hCG-primed and non-primed groups did not differ with respect to the clinical pregnancy (37.50% vs. 50.00%), live birth (22.50% vs. 30.95%), and implantation rates (32.86% vs. 32.56%). The pregnancy losses was 6 (40.00%) of 15 clinical pregnancies in the hCG-primed group, and 8 (38.10%) of 21 clinical pregnancies in the non-primed group.
  
  
  CONCLUSIONS
  While a significant improvement in the nuclear maturation rate of immature oocytes was observed in hCG-primed IVM cycles with PCOS patients, the use of hCG prior to oocyte retrieval did not improve the subsequent embryo developmental competence. The high rate of pregnancy loss in IVM cycles should receive more attention.
authors.affiliation: Department of Obstetrics and Gynecology, Center of Reproductive Medicine, Peking University, Third Hospital, Beijing, 100191, China.
authors.forename: Xiaoying
authors.initials: X
authors.lastname: Zheng
authors.forename: Lina
authors.initials: L
authors.lastname: Wang
authors.forename: Xiumei
authors.initials: X
authors.lastname: Zhen
authors.forename: Ying
authors.initials: Y
authors.lastname: Lian
authors.forename: Ping
authors.initials: P
authors.lastname: Liu
authors.forename: Jie
authors.initials: J
authors.lastname: Qiao
mesh_terms: D000328:Adult; D006063:Chorionic Gonadotropin / Q000494:pharmacology* / Q000627:therapeutic use; D010064:Embryo Implantation; D004624:Embryo Transfer; D047108:Embryonic Development / Q000187:drug effects*; D005260:Female; D006801:Humans; D059471:In Vitro Oocyte Maturation Techniques / Q000379:methods*; D007247:Infertility, Female / Q000188:drug therapy*; D054315:Oocyte Retrieval; D009865:Oocytes / Q000187:drug effects*; D011085:Polycystic Ovary Syndrome / Q000150:complications*; D011247:Pregnancy; D011256:Pregnancy Outcome; D018873:Pregnancy Rate
chemical_list: D006063:Chorionic Gonadotropin